Axsome Update: Buy At Dips And Hold Forever (NASDAQ:AXSM)

4 mins read

Axsome Therapeutics (NASDAQ:AXSM) is increasingly poised to become the single most important player in the Major Depressive Disorder space, with its Auvelity tracking ahead of market expectations. In the last quarter, Auvelity sales were $27.6 million, representing 76% quarter-over-quarter growth. Being the first andchart

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website feature a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you.

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Judge Chutkan holds hearing over proposed gag order against Trump in DC

Next Story

TikTok steps up efforts to counter misinformation about Israel-Hamas war

Latest from News